Monopar Therapeutics Other Current Assets

The latest other current assets for MNPR is $85B as of March 2026. That compares with $15B in the prior-year period — up 454.5% year over year. Investors often review this figure alongside Monopar Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MNPR's other current assets moved from $15B to $85B — a 454.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Monopar Therapeutics's operating scale or balance-sheet position.

A other current assets figure of $85B for MNPR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MNPR's other current assets ($85B), review year-over-year change from $15B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Monopar Therapeutics's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.